title: Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.
abstract: OBJECTIVE
  Prioritization of translational research on genomic tests is critically important given the rapid pace of innovation in genomics. The goal of this study was to evaluate a stakeholder-informed priority-setting framework in cancer genomics.
  
  
  METHODS
  An external stakeholder advisory group including patients/consumers, payers, clinicians, and test developers used a modified Delphi approach to prioritize six candidate cancer genomic technologies during a 1-day meeting. Nine qualitative priority-setting criteria were considered. We used a directed, qualitative content-analysis approach to investigate the themes of the meeting discussion.
  
  
  RESULTS
  Stakeholders primarily discussed six of the original nine criteria: clinical benefits, population health impacts, economic impacts, analytical and clinical validity, clinical trial implementation and feasibility, and market factors. Several new priority-setting criteria were identified from the workshop transcript, including "patient-reported outcomes," "clinical trial ethics," and "trial recruitment." The new criteria were incorporated with prespecified criteria to develop a novel priority-setting framework.
  
  
  CONCLUSIONS
  This study highlights key criteria that stakeholders can consider when prioritizing comparative effectiveness research for cancer genomic applications. Applying an explicit priority-setting framework to inform investment in comparative effectiveness research can help to ensure that critical factors are weighed when deciding between many potential research questions and trial designs.
authors.affiliation: Center for Medical Technology Policy, Baltimore, MD, USA. laura.esmail@gmail.com
authors.forename: Laura C
authors.initials: LC
authors.lastname: Esmail
authors.forename: Josh
authors.initials: J
authors.lastname: Roth
authors.forename: Sneha
authors.initials: S
authors.lastname: Rangarao
authors.forename: Josh J
authors.initials: JJ
authors.lastname: Carlson
authors.forename: Rahber
authors.initials: R
authors.lastname: Thariani
authors.forename: Scott D
authors.initials: SD
authors.lastname: Ramsey
authors.forename: David L
authors.initials: DL
authors.lastname: Veenstra
authors.forename: Patricia
authors.initials: P
authors.lastname: Deverka
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000235:genetics; D057186:Comparative Effectiveness Research / Q000379:methods / Q000592:standards; D004268:DNA-Binding Proteins / Q000235:genetics; D004720:Endonucleases / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005820:Genetic Testing / Q000379:methods / Q000592:standards; D023281:Genomics / Q000379:methods* / Q000592:standards; D006292:Health Priorities; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics; D009154:Mutation; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D057170:Translational Research, Biomedical / Q000379:methods* / Q000592:standards
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C512478:EGFR protein, human; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C071447:ERCC1 protein, human; D004720:Endonucleases